期刊文献+

免疫抑制剂在重症肌无力中的临床应用 被引量:6

Clinical Application of Immunosuppressive Agent in Myasthenia Gravis
下载PDF
导出
摘要 重症肌无力(myasthenia gravis,MG)是一种神经肌肉接头传递障碍的获得性自身免疫性疾病,病变部位在神经-肌肉接头的突触后膜,该膜上的抗乙酰胆碱受体(AChR)受到损害后,数目减少。MG发病原因包括自身免疫、被动免疫、药物(如D-青霉胺等)、感染等。MG每年平均发病率约为7.40/100 000(女性7.14/100 000,男性7.66/100 000)。
作者 杨维丽 黄志
出处 《儿科药学杂志》 CAS 2016年第2期56-59,共4页 Journal of Pediatric Pharmacy
  • 相关文献

参考文献33

  • 1重症肌无力诊断和治疗中国专家共识[J].中国神经免疫学和神经病学杂志,2012,19(6):401-408. 被引量:173
  • 2李保华,唐爱萍,姜海平,张润希,徐金枝,杨明山.小儿重症肌无力1381例临床综合分析[J].中国实用儿科杂志,2000,15(5):282-284. 被引量:29
  • 3COUTINHO A E, CHAPMAN K E. The anti-inflammatoryandimmunosuppressive effects of glucocorticoids, recentdevelopmentsand mechanistic insights [ J]. Mol Cell Endocrinol, 2011,335(1): 2-13.
  • 4ROGATSKY I,IVASHKIV L B. Glucocorticoid modulation ofcytokine signaling [J]. Tissue antigens, 2006, 68(1) ; 1-12.
  • 5ROZKOVA D, HORVATH R, BARTUNKOVA J,et al. Gluco-corticoids severely impairdifferentiation and antigen presentingfunction of dendritic cells despite upregulation of Toll-likereceptors [ J]. Clin Immunol, 2006,20(3) : 260-271.
  • 6FATTOHOSSI A, BATTAGLIA A,Buzzonetti A, et al. Circu-lating and thymic CD4 CD25 Tregulatory cells in myastheniagravis: Effect of immunosuppressive treatment [ J]. Immunology,2005, 116(1) ;134-141.
  • 7GILHUS N E,OWE J F,HOFF J M, et al. Myasthenia gravis: areview of available treatment approaches [ J ]. Autoimmune Dis,2011. doi; 10.4061/2011/847393.
  • 8HAINES S R1,THURTELL M J. Treatment of Ocular MyastheniaGravis [ J]. Current treatment options in neurology, 2012, 14(1):103-112.
  • 9KUPERSMITH M J. Ocular myasthenia gravis : treatment successesand failures in patients with long-term follow-up [ J ]. J Neurol,2009 , 256(8): 1314-1320.
  • 10LUCHANOK U, KAMINSKI H. Ocular myasthenia: diagnosticand treatment recommendations and the evidence base [ J ].Curr Opin Neurol, 2008, 21(1) : 8-15.

二级参考文献24

  • 1彭丹涛,许贤豪,佘子瑜.新斯的明试验改良结果判定法研究[J].中国神经免疫学和神经病学杂志,2007,14(1):1-3. 被引量:26
  • 2许贤豪.重症肌无力[M]//许贤豪主编.肌无力-临床与基础.北京:中国协和医科大学出版社,2003:46-75.
  • 3[7]Anlar B,Ozdirim E,Renda Y,et al.Myasthenia gravis in childhood.Acta Paediatr,1996;85(7):838
  • 4[8]Andrews PI,Massey JM,Sanders DB.Acetylcholine receptor antibodies in juvenile myasthenia gravis.Neurology,1993;43(5):977
  • 5[9]Palmisani MT,Evoli A,Batocchi AP,et al.Myasthenia gravis associated with thymoma.Eur Neurol,1994;34(1):78
  • 6[1]Andrews PI,Massey JM,Howard JF,et al.Race,sex,and puberty influence onset,severity,and outcome in juvenile myasthenia gravis.Neurology,1994;44:1208
  • 7[5]Millichap JG,Dodge PR.Diagnosis and treatment of myasthenia gravis in infancy,childhood,and adolescence.Neurology,1960;10(6):1007
  • 8Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treat- ment of autoimmune neuromuscular transmission disorders [J]. EurJ Neurol, 2010,17(7): 893-902.
  • 9Jani Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment[J]. J Neurol Sci, 2007, 261(1-2) :127-133.
  • 10Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis emerging clinical and biological heterogeneity [J]. Lancet Neurol, 2009, 8(5)475 490.

共引文献200

同被引文献53

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部